Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

NCT04603365 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped enrollment

Conditions

Clear Cell Papillary Renal Neoplasm
Collecting Duct Carcinoma
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Hereditary Papillary Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Metastatic Unclassified Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8
Stage IV Renal Cell Cancer AJCC v8
Tubulocystic Renal Cell Carcinoma
Unresectable Renal Cell Carcinoma

Interventions

DRUG: Pamiparib
DRUG: Temozolomide

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]